Influenza Therapeutics Market 2026

November 2025 | 243 pages | ID: I08C4F8E312AEN
DataM Intelligence

Abstracts

The Influenza Therapeutics Market was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Influenza Therapeutics Market.

This report delivers a comprehensive overview of the Influenza Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Influenza Therapeutics Market. The Influenza Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

Influenza Therapeutics Market Scope:

By Disease Type

• Influenza Type A
• Influenza Type B
• Influenza Type C
• Influenza Type D

By Therapeutics

• Medication
• Vaccines

By Route of Administration

• Oral
• Inhaled
• Injectables

By End User

• Hospitals and Clinics
• Specialty Centers
• Others

Key Players

• Merck KGaA
• Santa Cruz Biotechnology, Inc.
• Biosynth
• Teva Pharmaceuticals USA, Inc.
• Biorbyt Ltd.
• Thermo Fisher Scientific Inc.
• Steris Healthcare PVT Ltd.
• Genentech, Inc.
• Lupin Pharmaceuticals, Inc.
• BioCryst Pharmaceuticals, Inc.

Major Highlights

This report delivers a comprehensive overview of the Influenza Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Influenza Therapeutics Market. The Influenza Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Disease Type
3.2. Snippet by Therapeutics
3.3. Snippet by Route of Administration
3.4. Snippet by End user
3.5. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Driver
    4.1.1.1. Increasing clinical trials
    4.1.1.2. XX
  4.1.2. Restraints
    4.1.2.1. Side effects of Antiviral drug
    4.1.2.2. XX
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19
  6.1.1. Scenario Before COVID
  6.1.2. Scenario During COVID
  6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY DISEASE TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  7.1.2. Market Attractiveness Index, By Disease Type
7.2. Influenza Type A*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Influenza Type B
7.4. Influenza Type C
7.5. Influenza Type D

8. BY THERAPEUTICS

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
  8.1.2. Market Attractiveness Index, By Therapeutics
8.2. Medication*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    8.2.2.1. Antiviral Agents
      8.2.2.1.1. Baloxavir
      8.2.2.1.2. Oseltamivir
      8.2.2.1.3. Peramivir
      8.2.2.1.4. Others
    8.2.2.2. Anti-Microbial Agents
      8.2.2.2.1. Rimantadine
      8.2.2.2.2. Amantadine
      8.2.2.2.3. Others
8.3. Vaccines
  8.3.1. Inactivated Influenza Vaccine (IIV)
  8.3.2. Live Attenuated Influenza Vaccine (LAIV)
  8.3.3. Others

9. BY ROUTE OF ADMINISTRATION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.1.2. Market Attractiveness Index, By route of administration
9.2. Oral*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Inhaled
9.4. Injectables

10. BY END USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals and Clinics*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Centers
10.4. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.7.1. U.S.
    11.2.7.2. Canada
    11.2.7.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.7.1. Germany
    11.3.7.2. UK
    11.3.7.3. France
    11.3.7.4. Italy
    11.3.7.5. Spain
    11.3.7.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.7.1. Brazil
    11.4.7.2. Argentina
    11.4.7.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.7.1. China
    11.5.7.2. India
    11.5.7.3. Japan
    11.5.7.4. Australia
    11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Merck KGaA
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Financial Overview
  13.1.4. Key Developments
13.2. Santa Cruz Biotechnology, Inc.
13.3. Biosynth
13.4. Teva Pharmaceuticals USA, Inc.
13.5. Biorbyt Ltd.
13.6. Thermo Fisher Scientific Inc.
13.7. Steris Healthcare PVT Ltd.
13.8. Genentech, Inc.
13.9. Lupin Pharmaceuticals, Inc.
13.10. BioCryst Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE

1. APPENDIX

1.1. About Us and Services
1.2. Contact Us